Involvement of substance P and neurogenic inflammation in arsenic-induced early vascular dysfunction.
Vascular-related diseases, including Blackfoot Disease and atherosclerosis, are prominent clinical findings among populations residing in arseniasis areas. While oxidative stress provided a general but nonspecific mechanistic base for arsenic-induced endothelial cell damage in vitro, more specific mechanism is needed to explain the highly targeted vascular lesions induced by arsenic in vivo. Based on our previous studies, we hypothesized that arsenic exerted its action on blood vessels via the neurogenic inflammation process involving release of a neuropeptide (substance P) and activation of endothelial Neurokinin 1 (NK-1) receptor in vivo. Indeed, our present study demonstrated a significantly higher substance P levels in arsenic-treated tissues when compared to saline-treated controls indicating a rapid release of substance P under the influence of arsenic. Furthermore, the arsenic-induced vascular leakage could be significantly reduced when the neurogenic inflammation process was interrupted (via either disruption on the release of substance P, interference on the action of substance P, or blockage of endothelial NK-1 receptor) showing that the neurogenic inflammation process was indeed involved. Histamine release was not found to play a significant role in arsenic-induced vascular permeability change. Our present study affirmed a de novo concept that a pathophysiological mechanism involving the neurogenic release of substance P and activation of endothelial NK-1 receptor underlies the arsenic-induced vascular injury and dysfunction in vivo. This pathophysiological process constituted a two-tiered biological interaction between the nervous system and vascular system and therefore was not readily unveiled by traditional in vitro studies in the past. Our present finding unveiled an important de novo concept on arsenic vascular toxicity in vivo.
Chen
Shih-Chieh
SC
Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University and Department of Clinical Research, Kaohsiung Medical University Hospital, Taiwan, ROC.
Tsai
Ming-Hsien
MH
Wang
Hsiu-Jen
HJ
Yu
Hsin-Su
HS
Chang
Louis W
LW
D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D018053:Arsenites / Q000633:toxicity*; D002199:Capillary Permeability / Q000187:drug effects*; D002211:Capsaicin / Q000494:pharmacology; D004423:Ear; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism; D004785:Environmental Pollutants / Q000633:toxicity*; D006632:Histamine / Q000494:pharmacology; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D054833:Isoindoles; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D020078:Neurogenic Inflammation / Q000139:chemically induced / Q000378:metabolism*; D064729:Neurokinin-1 Receptor Antagonists; D010446:Peptide Fragments / Q000378:metabolism; D011738:Pyrilamine / Q000494:pharmacology; D018040:Receptors, Neurokinin-1 / Q000378:metabolism; D012867:Skin / Q000098:blood supply / Q000294:innervation; D017670:Sodium Compounds / Q000633:toxicity*; D013373:Substance P / Q000378:metabolism*; D013997:Time Factors
D000700:Analgesics; D018053:Arsenites; D004785:Environmental Pollutants; D006634:Histamine H1 Antagonists; D007211:Indoles; D054833:Isoindoles; D064729:Neurokinin-1 Receptor Antagonists; D010446:Peptide Fragments; D018040:Receptors, Neurokinin-1; D017670:Sodium Compounds; C071693:7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one; D013373:Substance P; C017947:sodium arsenite; C032682:substance P (4-11); D006632:Histamine; D011738:Pyrilamine; D002211:Capsaicin